Dr Christine Hauser
Honorary Fellow
The Sir Peter MacCallum Department of Oncology
18 Scholarly works
0 Projects
HIGHLIGHTS
2022
Conference Proceedings
Circulating tumor DNA and outcomes with lutetium-PSMA in advanced prostate cancer: Preliminary results from an Australian study
DOI: 10.1158/1538-7445.am2022-5322022
Journal article
177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial
DOI: 10.2967/jnumed.121.2625522022
Conference Proceedings
Prognostic and predictive utility of DNA damage response (DDR) aberrations detected in cell-free DNA (cfDNA) in metastatic castration-resistant prostate cancer (mCRPC).
DOI: 10.1200/JCO.2022.40.6_suppl.1532022
Conference Proceedings
Age-based assessment of cell-free DNA genomic profiles in metastatic castration-resistant prostate cancer (mCRPC).
DOI: 10.1200/JCO.2022.40.6_suppl.1502021
Journal article
Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor–treated Metastatic Castration-resistant Prostate Cancer
DOI: 10.1016/j.euf.2020.07.0012021
Conference Proceedings
Genomic landscape of older versus younger men with metastatic castration-resistant prostate cancer
2021
Journal article
Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer
DOI: 10.1002/pros.24194
RECENT SCHOLARLY WORKS
2021
Journal article
Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer
DOI: 10.21037/tau-20-14442021
Conference Proceedings
Plasma cell-free DNA profiling of PI3K/Akt pathway aberrations in two multi-institutional independent metastatic castration-resistant prostate cancer (mCRPC) cohorts.
DOI: 10.1200/JCO.2021.39.6_suppl.1592021
Journal article
Plasma cell-free dna profiling of pten-pi3kakt pathway aberrations in metastatic castration-resistant prostate cancer
DOI: 10.1200/PO.20.00424